Australia Stock Exchange release from PARADIGM BIOPHAR : PPS a new adjunct therapy treatment for patients with MPS VI
10/02/2022 23:04
Australia Stock Exchange release from PARADIGM BIOPHAR PAR.AX : PPS a new adjunct therapy treatment for patients with MPS VI
Recent news on Paradigm Biopharmaceuticals
See all newsBrief: Paradigm Biopharmaceuticals Says Board Initiates Voluntary Administration
Brief: Paradigm Biopharmaceuticals Seeks Trading Halt
Australia's Paradigm Biopharmaceuticals slips on discounted placement
Brief: Paradigm Biopharmaceuticals Says Co Completes A$14 Mln Placement
Brief: Paradigm Biopharmaceuticals Requests Trading Halt